Zhao Shujing, Li Kaixu, Wang Haiyu, Ding Yumin, Li Dehong
School of Public Health, Gansu University of Chinese Medicine, Lanzhou, China.
Department of Blood Transfusion, Gansu Provincial Hospital, Lanzhou, China.
Transl Cancer Res. 2025 Jun 30;14(6):3860-3873. doi: 10.21037/tcr-2024-2361. Epub 2025 Jun 18.
Carbohydrate antigens (CAs) are of great significance in various aspects of gastric cancer (GC). As new members of the family of CAs continue to be discovered, there is a growing focus on their role as therapeutic targets. The comprehensive review aims to provide an in-depth analysis of the current and evolving utilization of CAs in GC, offering valuable insights on the role of CAs as therapeutic targets or biomarkers for GC patients.
A detailed narrative review of the most recent literature was conducted to assess the current use and advancements of CAs in GC. PubMed database was being examined and the last run was on 8 June 2024.
This article traces the discovery and biological properties of CAs and their role in GC clinical practice. CAs not only serve a crucial clinical function in the diagnosis, therapy monitoring, metastatic evaluation, and prognosis of GC, but they also improve biological performance when paired with other biomarkers. New CAs, like truncated O-glycans, gangliosides, globo-series glycan, and Lewis antigens, significantly influence GC progression, metastatic infiltration, and individual susceptibility. Moreover, these antigens exhibit unique potential in GC treatment, offering new approaches and insights for GC treatment.
The use of CAs in GC diagnosis, prognosis, monitoring, and targeting therapy is beneficial. With the ongoing advancement of detection methodologies and technologies, challenges related to the sensitivity and specificity of CAs detection are anticipated to be progressively and effectively addressed. This will make its application in GC more widespread and effective.
碳水化合物抗原（CAs）在胃癌（GC）的各个方面都具有重要意义。随着CAs家族新成员不断被发现，人们越来越关注它们作为治疗靶点的作用。本综述旨在深入分析CAs在GC中的当前及不断发展的应用情况，为CAs作为GC患者的治疗靶点或生物标志物的作用提供有价值的见解。
对最新文献进行了详细的叙述性综述，以评估CAs在GC中的当前应用和进展。对PubMed数据库进行了检索，最后一次检索时间为2024年6月8日。
本文追溯了CAs的发现、生物学特性及其在GC临床实践中的作用。CAs不仅在GC的诊断、治疗监测、转移评估和预后中发挥关键的临床作用，而且与其他生物标志物联合使用时还能改善生物学性能。新的CAs，如截短的O-聚糖、神经节苷脂、球系列聚糖和Lewis抗原，对GC进展、转移浸润和个体易感性有显著影响。此外，这些抗原在GC治疗中展现出独特潜力，为GC治疗提供了新方法和见解。
CAs在GC诊断、预后、监测和靶向治疗中的应用是有益的。随着检测方法和技术的不断进步，预计与CAs检测的敏感性和特异性相关的挑战将逐步得到有效解决。这将使其在GC中的应用更加广泛和有效。
